Retatrutide: The Triple Agonist on the Horizon

Each new entry in the GLP-1 class arrives with bigger numbers, and retatrutide has produced the largest weight-loss figures reported so far in this category. It is worth understanding what makes it different and why “largest yet” is a claim that deserves both attention and restraint.

Retatrutide (Eli Lilly’s LY3437943) is a triple agonist: it activates the GLP-1 and GIP receptors, like tirzepatide, but adds a third target, the glucagon receptor. That third action is the interesting part, and also the source of most of the open questions.

Why a third receptor matters

GLP-1 and GIP agonism reduce appetite and improve how the body handles glucose. Glucagon receptor activation is different. Glucagon is often thought of only as a blood-sugar-raising hormone, but it also increases energy expenditure and can promote fat breakdown in the liver. The bet behind retatrutide is that adding controlled glucagon activity raises calorie burn on top of appetite suppression. Lime, 4k wallpaper, mac wallpaper — illustrating Retatrutide: The Triple Agonist on the Horizon

In its phase 2 obesity trial — published in The New England Journal of Medicine in 2023 by Jastreboff and colleagues, enrolling 338 adults — the highest 12 mg dose produced a 24.2% mean weight reduction at 48 weeks, compared with 2.1% on placebo. Lower doses followed a clear dose-response: −8.7% at 1 mg, −17.1% at 4 mg, and −22.8% at 8 mg. That 24.2% figure is the largest mean reduction reported for any agent in this class to date.

The honest limit: this is a single mid-stage trial in 338 selected participants. Large phase 3 outcome trials are still underway, and history in this class shows that real-world results are usually more modest than headline trial averages.

What we still do not know

Vegetables, fruits, food — illustrating Retatrutide: The Triple Agonist on the Horizon

How retatrutide compares head-to-head against tirzepatide and semaglutide over years, not months — no such trial has reported.
The glucagon component already shows dose-dependent heart-rate increases (peaking around 24 weeks before declining); whether other system effects emerge at scale is unresolved.
Long-term safety, since the longest published data covers 48 weeks.
What happens to weight after stopping — likely regain, as with the rest of the class, but unquantified for retatrutide specifically.

Reading the hype carefully

Watermelon, melon, colorful — illustrating Retatrutide: The Triple Agonist on the Horizon

It is genuinely possible that retatrutide ends up being the most effective agent in this class for weight loss. It is equally possible that the bigger effect comes with trade-offs that only large trials reveal. Both things can be true at once, and the early data cannot resolve which dominates.

The takeaway

Retatrutide is one of the most promising metabolic drugs in development, and the early signal — 24.2% at the top dose — is large enough to take seriously. But it is not approved, the data is mid-stage (one 48-week phase 2 trial), and “largest losses yet” describes a trial average, not a guarantee for any individual. Treat it as a compound to watch closely rather than a conclusion already reached.